{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T13:48:39Z","timestamp":1792244919219,"version":"4.4.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"vor","delay-in-days":66,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.beem.2026.102104","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T23:42:44Z","timestamp":1776814964000},"page":"102104","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Impulse control disorders and dopamine agonists"],"prefix":"10.1016","volume":"40","author":[{"given":"Ross","family":"Hamblin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgia","family":"Ntali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niki","family":"Karavitaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.beem.2026.102104_bib1","series-title":"Diagnostic and statistical manual of mental disorders: DSM-5","author":"American Psychiatric Association","year":"2013"},{"issue":"1","key":"10.1016\/j.beem.2026.102104_bib2","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1176\/appi.ajp.2018.18040465","article-title":"Impulse control disorders in Parkinson's disease","volume":"176","author":"Weintraub","year":"2019","journal-title":"Am J Psychiatry"},{"issue":"8","key":"10.1016\/j.beem.2026.102104_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.arcmed.2023.102910","article-title":"Impulse control disorders in patients with pituitary tumors treated with dopamine agonists: a systematic review","volume":"54","author":"Hamblin","year":"2023","journal-title":"Arch Med Res"},{"issue":"12","key":"10.1016\/j.beem.2026.102104_bib4","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/s41574-023-00886-5","article-title":"Diagnosis and management of prolactin-secreting pituitary adenomas: a pituitary society international consensus statement","volume":"19","author":"Petersenn","year":"2023","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.beem.2026.102104_bib5","doi-asserted-by":"crossref","DOI":"10.1093\/ejendo\/lvae003","article-title":"Efficacy of cabergoline in non-irradiated patients with acromegaly: a multi-centre cohort study","author":"Urwyler","year":"2024","journal-title":"Eur J Endocrinol"},{"issue":"12","key":"10.1016\/j.beem.2026.102104_bib6","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/S2213-8587(21)00235-7","article-title":"Consensus on diagnosis and management of Cushing's disease: a guideline update","volume":"9","author":"Fleseriu","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"10.1016\/j.beem.2026.102104_bib7","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/COC.0000000000000505","article-title":"Cabergoline in the management of residual nonfunctioning pituitary adenoma: a single-center, open-label, 2-year randomized clinical trial","volume":"42","author":"Batista","year":"2019","journal-title":"Am J Clin Oncol"},{"issue":"5","key":"10.1016\/j.beem.2026.102104_bib8","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1001\/archneurol.2010.65","article-title":"Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients","volume":"67","author":"Weintraub","year":"2010","journal-title":"Arch Neurol"},{"issue":"12","key":"10.1016\/j.beem.2026.102104_bib9","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1001\/jamainternmed.2014.5262","article-title":"Reports of pathological gambling, hypersexuality, and compulsive shopping associated with dopamine receptor agonist drugs","volume":"174","author":"Moore","year":"2014","journal-title":"JAMA Intern Med"},{"issue":"6","key":"10.1016\/j.beem.2026.102104_bib10","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1002\/mds.27689","article-title":"Scales to assess impulsive and compulsive behaviors in Parkinson's disease: critique and recommendations","volume":"34","author":"Evans","year":"2019","journal-title":"Mov Disord"},{"issue":"3","key":"10.1016\/j.beem.2026.102104_bib11","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1007\/s00415-021-10724-1","article-title":"Risk factors of impulsive-compulsive behaviors in PD patients: a meta-analysis","volume":"269","author":"Cao","year":"2022","journal-title":"J Neurol"},{"issue":"12","key":"10.1016\/j.beem.2026.102104_bib12","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1038\/ncpneuro0680","article-title":"Drug Insight: impulse control disorders and dopamine therapies in Parkinson's disease","volume":"3","author":"Potenza","year":"2007","journal-title":"Nat Clin Pract Neurol"},{"issue":"3","key":"10.1016\/j.beem.2026.102104_bib13","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s11102-025-01517-0","article-title":"Impulse control disorders in patients with pituitary adenoma managed with or without dopamine agonists: a cross-sectional study from a UK centre","volume":"28","author":"Hamblin","year":"2025","journal-title":"Pituitary"},{"issue":"5","key":"10.1016\/j.beem.2026.102104_bib14","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/WNF.0b013e3182281b2f","article-title":"Impulse control disorders associated with dopaminergic medication in patients with pituitary adenomas","volume":"34","author":"Martinkova","year":"2011","journal-title":"Clin Neuropharmacol"},{"issue":"6","key":"10.1016\/j.beem.2026.102104_bib15","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1111\/cen.12375","article-title":"Impulse control disorders in patients with dopamine agonist-treated prolactinomas and nonfunctioning pituitary adenomas: a case-control study","volume":"80","author":"Bancos","year":"2014","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"10.1016\/j.beem.2026.102104_bib16","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1007\/s12020-018-1744-8","article-title":"Impulse control disorders in patients with prolactinoma receiving dopamine agonist therapy: a prospective study with 1 year follow-up","volume":"62","author":"Celik","year":"2018","journal-title":"Endocrine"},{"issue":"7","key":"10.1016\/j.beem.2026.102104_bib17","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1210\/jc.2018-02202","article-title":"Dopamine agonist-induced impulse control disorders in patients with prolactinoma: a cross-sectional multicenter study","volume":"104","author":"Dogansen","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.beem.2026.102104_bib18","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgz076","article-title":"Impulse control disorders in dopamine agonist-treated hyperprolactinemia: prevalence and risk factors","volume":"105","author":"De Sousa","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2026.102104_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.ghir.2020.101356","article-title":"Patients with acromegaly might not be at higher risk for dopamine agonist-induced impulse control disorders than those with prolactinomas","volume":"55","author":"Ozkaya","year":"2020","journal-title":"Growth Horm IGF Res"},{"issue":"8","key":"10.1016\/j.beem.2026.102104_bib20","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1007\/s40618-020-01478-0","article-title":"Increased prevalence of impulse control disorder symptoms in endocrine diseases treated with dopamine agonists: a cross-sectional study","volume":"44","author":"Beccuti","year":"2021","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.beem.2026.102104_bib21","article-title":"Effect of dopaminergic therapy on impulse control disorders in patients with a prolactinoma","volume":"26","author":"Ozdeniz Varan","year":"2022","journal-title":"Cogn Behav Neurol: J Soc Behav Cogn Neurol"},{"issue":"6","key":"10.1016\/j.beem.2026.102104_bib22","doi-asserted-by":"crossref","first-page":"e275","DOI":"10.1210\/clinem\/dgac718","article-title":"A genetic assessment of dopamine agonist-induced impulse control disorder in patients with prolactinoma","volume":"108","author":"Sahin","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.beem.2026.102104_bib23","doi-asserted-by":"crossref","first-page":"107","DOI":"10.4103\/0028-3886.370452","article-title":"Impulse control disorders with short-term use of cabergoline in macroprolactinomas: a prospective study with a brief review of literature","volume":"71","author":"Sanjan","year":"2023","journal-title":"Neurol India"},{"issue":"4","key":"10.1016\/j.beem.2026.102104_bib24","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s11102-023-01342-3","article-title":"Risk of impulse control disorders in patients with Cushing's disease: do not blame cabergoline but do not give up caution","volume":"26","author":"Sulu","year":"2023","journal-title":"Pituitary"},{"issue":"4","key":"10.1016\/j.beem.2026.102104_bib25","article-title":"Impulse control disorders in southern iraqi patients medicated with cabergoline for prolactinoma","volume":"16","author":"Mohammad","year":"2024","journal-title":"Cureus"},{"issue":"1","key":"10.1016\/j.beem.2026.102104_bib26","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s12902-022-01009-3","article-title":"The side effects of dopamine receptor agonist drugs in Chinese prolactinoma patients: a cross sectional study","volume":"22","author":"Ke","year":"2022","journal-title":"BMC Endocr Disord"},{"issue":"2","key":"10.1016\/j.beem.2026.102104_bib27","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1007\/s12020-016-1088-1","article-title":"Dopa-testotoxicosis: disruptive hypersexuality in hypogonadal men with prolactinomas treated with dopamine agonists","volume":"55","author":"De Sousa","year":"2017","journal-title":"Endocrine"},{"key":"10.1016\/j.beem.2026.102104_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2020.579606","article-title":"Depression and impulsivity self-assessment tools to identify dopamine agonist side effects in patients with pituitary adenomas","volume":"11","author":"Hinojosa-Amaya","year":"2020","journal-title":"Front Endocrinol"},{"issue":"0","key":"10.1016\/j.beem.2026.102104_bib29","article-title":"Prevalence and risk factors of dopamine agonists induced impulse control disorders in patients with prolactinoma","volume":"0","author":"Zhang","year":"2025","journal-title":"Int J Psychiatry Med"},{"key":"10.1016\/j.beem.2026.102104_bib30","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jpsychires.2026.01.041","article-title":"Cabergoline and impulse control disorders: screening patients with pituitary adenomas in an endocrinology clinic","volume":"195","author":"Lydiatt","year":"2026","journal-title":"J Psychiatr Res"},{"issue":"2","key":"10.1016\/j.beem.2026.102104_bib31","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s11102-024-01383-2","article-title":"Impulse control disorders in patients with dopamine agonist-treated pituitary adenomas: a cross-sectional multicenter study","volume":"27","author":"Almalki","year":"2024","journal-title":"Pituitary"},{"key":"10.1016\/j.beem.2026.102104_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.jocn.2025.111363","article-title":"Impulse control disorders in prolactinoma patients treated with dopamine agonists: a systematic review and meta-analysis with trial sequential analysis","volume":"138","author":"Penchev","year":"2025","journal-title":"J Clin Neurosci"},{"issue":"4","key":"10.1016\/j.beem.2026.102104_bib33","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1176\/jnp.2007.19.4.473","article-title":"Pathological gambling associated with cabergoline therapy in a patient with a pituitary prolactinoma","volume":"19","author":"Davie","year":"2007","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"10.1016\/j.beem.2026.102104_bib34","doi-asserted-by":"crossref","first-page":"465","DOI":"10.3389\/fpsyt.2018.00465","article-title":"Parkinson's disease: impulsivity does not cause impulse control disorders but boosts their severity","volume":"9","author":"Mar\u00edn-Lahoz","year":"2018","journal-title":"Front Psychiatry"},{"issue":"3","key":"10.1016\/j.beem.2026.102104_bib35","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.parkreldis.2010.11.015","article-title":"Patient versus informant reporting of ICD symptoms in Parkinson's disease using the QUIP: validity and variability","volume":"17","author":"Papay","year":"2011","journal-title":"Park Relat Disord"},{"issue":"1","key":"10.1016\/j.beem.2026.102104_bib36","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/mdc3.13128","article-title":"Does the country make a difference in impulse control disorders? A systematic review","volume":"8","author":"Parra-D\u00edaz","year":"2021","journal-title":"Mov Disord Clin Pr"},{"issue":"3","key":"10.1016\/j.beem.2026.102104_bib37","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1159\/000335996","article-title":"Distinct dopaminergic personality patterns in patients with prolactinomas: a comparison with nonfunctioning pituitary adenoma patients and age- and gender-matched controls","volume":"96","author":"Athanasoulia","year":"2012","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.beem.2026.102104_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.ghir.2021.101439","article-title":"Personality traits in acromegalic patients: comparison with patients with non-functioning adenomas and healthy controls","volume":"62","author":"Kan","year":"2022","journal-title":"Growth Horm IGF Res"},{"issue":"3","key":"10.1016\/j.beem.2026.102104_bib39","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1530\/EJE-08-0896","article-title":"Personality in patients with pituitary adenomas is characterized by increased anxiety-related traits: comparison of 70 acromegalic patients with patients with non-functioning pituitary adenomas and age-and gender-matched controls","volume":"160","author":"Sievers","year":"2009","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"10.1016\/j.beem.2026.102104_bib40","first-page":"81","article-title":"Impulse control disorders with the use of dopaminergic agents in restless legs syndrome: a case-control study","volume":"33","author":"Cornelius","year":"2010","journal-title":"Sleep"}],"container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X26000254?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X26000254?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T11:18:41Z","timestamp":1788866321000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521690X26000254"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S1521690X26000254"],"URL":"https:\/\/doi.org\/10.1016\/j.beem.2026.102104","relation":{},"ISSN":["1521-690X"],"issn-type":[{"value":"1521-690X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impulse control disorders and dopamine agonists","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Endocrinology & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beem.2026.102104","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102104"}}